Contact Lenses
SofLens® daily disposable contact lenses
Key Features & Benefits
-
Outstanding all-day comfort that is preferred to competitive daily disposable lenses
-
High Definition™ Optics reduces the appearance of blurriness, halos, and glare across a full range of conditions
-
No daily cleaning, storage, or care required; wear them for a day, then, throw them away
Product Detail Information
Is this product right for you?
- Condition(s) Nearsightedness (myopia), Farsightedness (hyperopia)
The Ultimate Combination of
Comfort and Vision.
SofLens® daily disposable contact lenses combine outstanding all-day comfort with incredibly crisp, clear vision, especially at night. SofLens delivers all the benefits of other daily disposable lenses and much more – giving you the ultimate lens-wearing experience.

Outstanding all-day comfort
SofLens® daily disposable lenses achieve a high level of comfort through ComfortMoist™ Technology – our unique lens design and innovative packaging solution. The lens design is exceptionally thin, allowing for a remarkably natural feel on the eye. The slow-release packaging solution creates a cushion of moisture around the lenses – keeping your eyes comfortable all day through the end of the day.
Crisp, clear vision, especially at night
SofLens® is the first daily disposable lens with High Definition™ Optics – a technology that reduces the appearance of blurriness, halos, and glare across a full range of conditions. The result is crisp, clear vision no matter the time or place, and especially in low-light situations.


* Simulated retinal image.
Easy to handle
- Convenient lens pack features easy-to-grip tab and tear-away label
- Ergonomic blister pack enables smooth lens removal
Note for current SofLens® one day contact lens users:
Please note: SofLens® one day lenses were discontinued in May, 2008. Ask your eye care professional about SofLens daily disposable contact lenses. 100% of patients upgrade seamlessly from SofLens one day to SofLens daily disposable lenses with no change in lens powers2.
22007 study of 75 patients. Data on file. Bausch & Lomb Incorporated.
